Martinsried/Munich, 5 August 2016. Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T-cell immunotherapies for the treatment of cancer, today reports financial results and corporate updates for the first six months of 2016.
Major events since the beginning of 2016:
Immunotherapies:
• Phase II of Phase I/II trial with DC vaccine for the treatment of acute myeloid leukaemia (AML) initiated following positive recommendation by DSMB
• Collaboration started with Max Delbrück Center and The Charité in Berlin for Germany`s first investigator-initiated clinical TCR trial
• DC platform and TCR platform strengthened by new patents
• Additional viral vector production capacities secured for clinical TCR trials
Major events since the beginning of 2016:
Immunotherapies:
• Phase II of Phase I/II trial with DC vaccine for the treatment of acute myeloid leukaemia (AML) initiated following positive recommendation by DSMB
• Collaboration started with Max Delbrück Center and The Charité in Berlin for Germany`s first investigator-initiated clinical TCR trial
• DC platform and TCR platform strengthened by new patents
• Additional viral vector production capacities secured for clinical TCR trials
